What happens when insurers and pharmaceutical manufacturers sit down at the same table to discuss the costs of private drug plans? Unanimous agreement that improved collaboration is essential to safeguard sustainability.
Nine insurers representing 16 million plan member lives and seven pharmaceutical companies were among the participants in the 2013 Canadian Leadership Council on Drug Plan Partnerships, which convened in June. Case studies and workshop sessions helped guide discussions and identify action steps for partnering in several key areas, including access to care and adherence to therapy. Read the highlights here.